Clinical trial NCT02507011: Beta-blockers in Pulmonary Arterial Hypertension
Official title: Beta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy, and Safety of Carvedilol for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Pulmonary Arterial Hypertension
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2015-07-23
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) \< 45% for 6 months.

Detailed description: Adult PAH patients on a stable dose of an approved PAH medication will undergo the following baseline assessments: cardiac magnetic resonance imaging (MRI), right heart catheterization (RHC), echocardiogram, 6-minute walk test (6-MWT), plasma NT-ProBNP (biomarkers of RV function) and serum catecholamine (measure of sympathetic activation), and quality of life. Patients will be randomized to carvedilol (3.125 mg bid and escalated to 9.375 mg bid, as tolerated, over 3 months) or placebo in a 1:1 fashion. After 6 months, testing is repeated and patients are crossed over to the alternate treatment. Testing is repeated at the end of the study (month 13).

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* WHO category 1 pulmonary arterial hypertension (Nice 2013)
* WHO functional class II-III
* RVEF by cardiac MRI \< 45%
* Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and functional class in the past 3 months. Patient can be on either mono or combination PAH-specific therapy

Exclusion Criteria:

* Subjects will be excluded from participation in the study if any of the following conditions exist:
* Significant persistent bradycardia (resting heart rate \< 60 bpm) without a permanent pacemaker
* Second or third degree AV block without a permanent pacemaker
* Significant sinus tachycardia (resting heart rate \> 110 bpm)
* Use of anti-arrhythmic drugs
* Hypotension defined as systolic blood pressure \< 100 mmHg at the time of enrollment
* Significant illness in the past 30 days requiring hospitalization
* Acute decompensated right heart failure within past 30 days
* Known allergy or intolerance to carvedilol or other β blockers
* Cardiac index \< 2 l/min/m2 or right atrial pressure \> 15 mm Hg by right heart catheterization within last 3 months
* Asthma
* Positive pregnancy test in patients of child bearing-potential

Primary outcomes:
measure: Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota Medical Center
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Thenappan Thenappan, MD
role: PRINCIPAL_INVESTIGATOR
References: